For Healthcare Professionals

Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia

clipboard-pencil

About the study

Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

  1. Male or female in good general health
  2. Must have presbyopia

EXCLUSION CRITERIA

Exclusion Criteria:

  1. History of allergic reaction to the study drug or any of its components
  2. Any disease or medical condition that, in the opinion of the Investigator, would prevent the subject from participating in the study or might confound study results
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition

Presbyopia

Age (in years)

45 - 80

Phase

Phase 3

Participants needed

450

Est. Completion Date

May 31, 2023

Treatment type

Interventional


Sponsor

Visus Therapeutics

ClinicalTrials.gov identifier

NCT05135286

Study number

VT-003

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.